10-Q: CEL-SCI Reports Q3 2026 Results, Faces Going Concern Doubt

CEL-SCI Corporation's Q3 2026 10-Q filing reveals significant net losses and substantial doubt about its ability to continue as a going concern, despite promising clinical data for its lead drug candidate, Multikine.

Summary

• CEL-SCI Corporation filed its quarterly report for the period ending June 30, 2026.
• The company reported a net loss of $16,602,722 for the nine months ended June 30, 2026, compared to a net loss of $19,310,155 for the same period in 2025.
• Total operating expenses for the nine months ended June 30, 2026, were $16,252,100, a decrease from $18,776,404 in the prior year.
• Cash and cash equivalents decreased to $6,527,381 as of June 30, 2026, from $10,953,460 as of September 30, 2025.
• The company continues to face substantial doubt about its ability to continue as a going concern due to recurring losses and future liquidity needs.
• CEL-SCI is focused on developing Multikine for head and neck cancers and LEAPS technology for rheumatoid arthritis.
• The company plans to raise additional capital through corporate partnerships, debt, or equity financings to fund its operations and the confirmatory registration study for Multikine, estimated to cost $30-$35 million.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's continued substantial doubt about its ability to continue as a going concern, significant net losses, and reliance on future capital raises, despite promising clinical trial data for Multikine.

Positives

• The Phase III study for Multikine showed a 73% survival rate at 5 years in the target population compared to 45% in the control group.
• Multikine demonstrated a significant reduction in the risk of death by 66% in the target population (hazard ratio of 0.34).
• The company received FDA indication to move forward with a confirmatory registration study for Multikine.
• No significant safety signals or toxicities were observed in approximately 740 Multikine-treated subjects across multiple clinical trials.
• CEL-SCI published comprehensive results from its Phase 3 trial in the peer-reviewed journal Pathology and Oncology Research (POR) in March 2025, including new data on quality of life improvements.
• The company entered into a Distribution Agreement with Saudi Amarox Co. for the registration, commercialization, and distribution of Multikine in Saudi Arabia.

Negatives

• The company has incurred significant losses since inception and faces substantial doubt about its ability to continue as a going concern.
• Net loss for the nine months ended June 30, 2026, was $16,602,722.
• Cash and cash equivalents decreased by approximately $4.4 million during the nine months ended June 30, 2026.
• The company will require substantial additional capital to fund its operations and the planned confirmatory registration study for Multikine.
• The ability to raise necessary capital is dependent on market conditions outside the company's control.
• Disclosure controls and procedures were not effective as of June 30, 2026, due to material weaknesses previously identified.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern due to recurring losses and future liquidity needs.
• The company's ability to raise additional capital is uncertain and dependent on market conditions.
• Obtaining regulatory approval for Multikine from the FDA and other agencies is uncertain.
• The cost of the confirmatory registration study is estimated at $30-$35 million, requiring significant future financing.
• If the company cannot raise sufficient funds, it may have to curtail its operations.
• The company has not generated any revenue and cannot predict when it will be able to generate revenue from product sales.

Future Outlook

The company plans to raise additional capital through corporate partnerships, debt, or equity financings to fund its operations and the confirmatory registration study for Multikine, estimated to cost $30-$35 million. The success of these efforts is crucial for continued operations and product development.

Management Comments

• "Due to the Companys recurring losses from operations and future liquidity needs, there is substantial doubt about the Companys ability to continue as a going concern and may be unable to realize its assets and discharge its liabilities in the normal course of business."
• "The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase III study in one of the two treatment arms for advanced primary head and neck cancer."
• "The cost of the confirmatory registration study is currently estimated to be about $30-$35 million. The Company will be required to raise additional capital or find additional long-term financing to continue with its research efforts."

Industry Context

StockSavvy.ai notes that CEL-SCI operates in the rapidly growing global cancer immunotherapy market, which is projected to reach $196.45 billion by 2030. However, the company faces intense competition and regulatory hurdles in bringing its novel therapy, Multikine, to market.

Comparison to Industry Standards

• CEL-SCI's Phase III trial results for Multikine in the target population (low PD-L1 expression, no lymph node involvement) show a 73% 5-year survival rate, significantly outperforming the 45% survival rate in the control group. This contrasts with checkpoint inhibitors like Keytruda, which primarily benefit patients with high PD-L1 expression and showed a 30% reduction in recurrence/progression risk but no overall survival improvement in a similar patient population.
• The hazard ratio of 0.35 for Multikine in the target population indicates a significantly lower risk of death compared to standard of care, a metric often scrutinized by regulatory bodies.
• The company's focus on a specific patient subgroup (low PD-L1) addresses an unmet need, as current therapies like Keytruda are less effective in this segment.
• The estimated cost of the confirmatory study ($30-$35 million) is substantial but may be considered within the range for late-stage oncology trials, though the company's ability to fund it is a key concern.

Related Party Transactions

• During the nine months ended June 30, 2026, the Company's CEO and the de Clara Trust purchased 446,412 shares of restricted common stock for approximately $729,000.
• During the three months ended June 30, 2026, the Company's CEO and the de Clara Trust purchased 400,000 shares of restricted common stock for approximately $479,000.

Stakeholder Impact

• Shareholders face continued uncertainty regarding the company's going concern status and the significant capital required for future development.
• Employees may be concerned about job security given the company's financial situation and reliance on future funding.
• Patients with advanced primary head and neck cancer may benefit from the potential approval of Multikine, which has shown promising survival data.
• Creditors and suppliers may face risks associated with the company's ability to meet its financial obligations.

Next Steps

• Begin the 212-patient confirmatory registration study for Multikine as soon as needed capital has been raised.
• Achieve full enrollment of the confirmatory study approximately 18-24 months after commencement.
• Seek early approval for Multikine after full enrollment of the confirmatory study.
• Continue to develop LEAPS technology for potential treatment of rheumatoid arthritis.

Key Dates

Recommendation

While the clinical data for Multikine is compelling and addresses an unmet need, the company's precarious financial situation, substantial doubt about its going concern status, and ongoing need for significant capital raise warrant a cautious 'hold' recommendation. Investors should monitor the company's ability to secure funding and advance its regulatory strategy.

Keywords

CEL-SCI, Multikine, Head and Neck Cancer, Immunotherapy, Clinical Trial, Biotechnology, Phase III, FDA